Ligand validation:2C3E

CDL: CARDIOLIPIN

CDL is a Ligand Of Interest in 2C3E designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
2C3E_CDL_A_801	13%	50%	0.252	0.874	0.8	1.14	2	6	3	0	55%	0.55
2C3E_CDL_A_800	5%	55%	0.299	0.785	0.7	1.02	1	5	3	0	62%	0.62
2C3E_CDL_A_802	2%	58%	0.348	0.662	0.7	0.88	3	5	2	0	81%	0.81
1OKC_CDL_A_800	13%	56%	0.242	0.863	0.65	1.03	-	6	1	0	57%	0.57
5Y5S_CDL_M_415	41%	36%	0.128	0.953	1.32	1.27	3	3	1	0	39%	0.39
2GNU_CDL_M_1309	38%	24%	0.122	0.984	1.77	1.5	3	3	0	0	10%	10
3ZDQ_CDL_A_1721	37%	64%	0.215	0.943	0.72	0.65	4	4	0	1	84%	0.42
6JY3_CDL_B_301	33%	27%	0.163	0.908	1.53	1.57	5	14	0	0	64%	0.64
7COH_CDL_A_521	33%	72%	0.212	0.901	0.46	0.6	-	2	6	0	94%	0.94

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.